

The Recent Federal Circuit Decision in *Acorda Therapeutics v. Mylan Pharmaceuticals* May Not be the Last Word on Jurisdiction in ANDA Cases

April 25, 2016 Mini Kapoor

PRACTICES Chemical, Intellectual Property, Hatch-Waxman/ANDA, Biosimilars

On March 18, 2016, the Federal Circuit held that Mylan Pharmaceuticals, Inc. (“**Mylan**”), a generic drug manufacturer, was subject to specific jurisdiction in Delaware because of Mylan’s filing an abbreviated new drug application (“**ANDA**”) and “contemplate[d] plans to engage in marketing of the proposed generic drugs” in the state. The ruling affirmed two different decisions by judges in the United States District Court for the District of Delaware that Mylan was subject to specific jurisdiction in Delaware.

[Read the full article.](#)